Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study

By sjmartinez • December 24, 2025

Abe K, Holmes TH, Nguyen TT; IMPACC Network; Kim-Schulze S, Levy O, Baden LR, Melamed E, Ehrlich LIR, McComsey GA, Sekaly RP, Cairns CB, Haddad EK, Shaw AC, Hafler DA, Montgomery RR, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Agudelo Higuita NI, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Fernandez-Sesma A, Simon V, Kraft M, Bime C, Calfee CS, Erle DJ, Schaenman J, Reed EF, Ozonoff A, Peters B, Kleinstein SH, Augustine AD, Diray-Arce J, Becker PM, Rouphael N, Maecker HT. Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study. J Immunol. 2025 Dec 1;214(12):3310-3320. doi: 10.1093/jimmun/vkaf263. PMID: 41166719; PMCID: PMC12726064.

Tags: Cytokines, human, Infectious Diseases, Inflammation, Molecular biology, Publications, viral

Beyond Ceftriaxone: The Future of Gonorrhea Diagnosis and Treatment

Allan-Blitz LT, Klausner JD. Beyond Ceftriaxone: The Future of Gonorrhea Diagnosis and Treatment. Clin Infect Dis. 2026 Jun 12:ciag214. doi: 10.1093/cid/ciag214. Epub ahead of print.[...]

Motivations for testing and linkage to HIV services following HIV self-testing among fishermen in Kenya: a qualitative analysis

Nishimura H, Agot K, Gutin SA, Olugo P, Lewis-Kulzer J, Kwena Z, Thorp M, Ayieko B, Thirumurthy H, Camlin CS. Motivations for testing and linkage[...]

Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide

Olson TE, Lloyd TS, Hamad CD, Chun RF, Wiener J, Golzar A, Mehany J, Shahamatdar S, Kittredge A, Pearce L, Francis KP, Obeidin F, Holly[...]